Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacy

23 Apr 2025

Abstract excerpt

The main protease (M Pro ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a validated drug target. Starting with a lead-like dihydrouracil chemotype identified in a large-library docking campaign, we improved M Pro inhibition >1000-fold by engaging additional M Pro subsites and using a latent electrophile to engage Cys 145 . Advanced leads from this series show pan-coronavirus antiviral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40267184
DOI: 10.1126/sciadv.adt7836

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacyPMID 40267184Read ↗

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M <sup>Pro</sup> inhibitors with potent in vivo efficacySemantic proximity Read ↗

Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screeningSemantic proximity Read ↗

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Bio-Logical and Pharmacological ProfilingSemantic proximity Read ↗

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19Semantic proximity Read ↗

Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19Semantic proximity Read ↗

Novel inhibitors against COVID-19 main protease suppressed viral infectionSemantic proximity Read ↗

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitorSemantic proximity Read ↗

High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent InhibitorSemantic proximity Read ↗

Structural basis for the inhibition of coronaviral main proteases by PF-00835231.Semantic proximity Read ↗

Structural basis for the inhibition of coronaviral main proteases by PF-00835231Semantic proximity Read ↗

Combating Antiviral Drug Resistance: A Multipronged Strategy.Semantic proximity Read ↗

Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.